Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice

Romiplostim had demonstrated efficacy in clinical trials for immune thrombocytopenia, but real-world effectiveness and safety data across the full spectrum of ITP disease phases in US hematology practice were lacking.

Target RWE researchers analyzed real-world data to characterize the effectiveness and safety of romiplostim across ITP disease phases in US hematology clinics, documenting response rates, adverse events, and treatment duration patterns.

Establishing romiplostim's real-world effectiveness and safety profile across ITP phases provides Amgen with post-authorization evidence supporting label communications and formulary positioning.

Romiplostim real-world effectiveness and safety characterization across ITP phases for Amgen post-authorization evidence, Post-market surveillance evidence supporting romiplostim label and formulary strategy in ITP